AI to Reduce the Interval Cancer Rate of Screening Digital Breast Tomosynthesis

Background Given the lack of long-term outcome data for screening digital breast tomosynthesis (DBT), the interval cancer rate is a commonly used surrogate for patient outcomes. Purpose To evaluate the performance of an artificial intelligence (AI) algorithm in detecting and localizing interval canc...

Full description

Saved in:
Bibliographic Details
Published inRadiology Vol. 316; no. 1; p. e241050
Main Authors Bahl, Manisha, Langarica, Saul, Lamb, Leslie R, Kniss, Ariel S, Do, Synho
Format Journal Article
LanguageEnglish
Published United States 01.07.2025
Subjects
Online AccessGet more information
ISSN1527-1315
DOI10.1148/radiol.241050

Cover

Abstract Background Given the lack of long-term outcome data for screening digital breast tomosynthesis (DBT), the interval cancer rate is a commonly used surrogate for patient outcomes. Purpose To evaluate the performance of an artificial intelligence (AI) algorithm in detecting and localizing interval cancers at screening DBT and to validate the diagnostic threshold of the algorithm by analyzing its performance across interval, true-positive, true-negative, and false-positive screening DBT examinations. Materials and Methods Screening DBT examinations performed immediately before confirmed interval cancer diagnoses between February 2011 and June 2023 at an academic institution were retrospectively analyzed by a U.S. Food and Drug Administration-cleared AI algorithm. Lesions marked by AI on DBT sections were assigned a score from 0 to 100, with the examination-level score reflecting the highest lesion score. AI-positive examinations (score ≥10) were independently reviewed by two breast imaging radiologists to determine whether AI annotations corresponded to the site of the subsequent cancer. Imaging and clinicopathologic features were compared between interval cancers detected and not detected by AI using the Wilcoxon signed rank test and Fisher exact test. Using the same threshold score, 1000 true-positive, true-negative, and false-positive screening DBT examinations were also analyzed by AI. Results Among 224 interval cancers in 224 women (mean age, 61 years ± 14 [SD]), AI correctly localized 32.6% (73 of 224) of the cancers at retrospective evaluation of the screening DBT examinations. Features associated with interval cancers detected by AI (versus not detected) included larger size at surgical pathology (37 vs 22 mm; < .001) and axillary lymph node positivity (41.3% [26 of 63] vs 22.8% [28 of 123]; = .01). Using the same threshold (score of 10 or greater considered positive), AI correctly localized 84.4% (282 of 334) of screening-detected (true-positive) cancers and correctly categorized 85.9% (286 of 333) and 73.3% (244 of 333) of true-negative and false-positive cases, respectively, as negative. Conclusion AI correctly localized nearly one-third of interval cancers at retrospective evaluation of screening DBT examinations and has the potential to decrease the interval cancer rate. © RSNA, 2025 See also the editorial by Lee and Milch in this issue.
AbstractList Background Given the lack of long-term outcome data for screening digital breast tomosynthesis (DBT), the interval cancer rate is a commonly used surrogate for patient outcomes. Purpose To evaluate the performance of an artificial intelligence (AI) algorithm in detecting and localizing interval cancers at screening DBT and to validate the diagnostic threshold of the algorithm by analyzing its performance across interval, true-positive, true-negative, and false-positive screening DBT examinations. Materials and Methods Screening DBT examinations performed immediately before confirmed interval cancer diagnoses between February 2011 and June 2023 at an academic institution were retrospectively analyzed by a U.S. Food and Drug Administration-cleared AI algorithm. Lesions marked by AI on DBT sections were assigned a score from 0 to 100, with the examination-level score reflecting the highest lesion score. AI-positive examinations (score ≥10) were independently reviewed by two breast imaging radiologists to determine whether AI annotations corresponded to the site of the subsequent cancer. Imaging and clinicopathologic features were compared between interval cancers detected and not detected by AI using the Wilcoxon signed rank test and Fisher exact test. Using the same threshold score, 1000 true-positive, true-negative, and false-positive screening DBT examinations were also analyzed by AI. Results Among 224 interval cancers in 224 women (mean age, 61 years ± 14 [SD]), AI correctly localized 32.6% (73 of 224) of the cancers at retrospective evaluation of the screening DBT examinations. Features associated with interval cancers detected by AI (versus not detected) included larger size at surgical pathology (37 vs 22 mm; < .001) and axillary lymph node positivity (41.3% [26 of 63] vs 22.8% [28 of 123]; = .01). Using the same threshold (score of 10 or greater considered positive), AI correctly localized 84.4% (282 of 334) of screening-detected (true-positive) cancers and correctly categorized 85.9% (286 of 333) and 73.3% (244 of 333) of true-negative and false-positive cases, respectively, as negative. Conclusion AI correctly localized nearly one-third of interval cancers at retrospective evaluation of screening DBT examinations and has the potential to decrease the interval cancer rate. © RSNA, 2025 See also the editorial by Lee and Milch in this issue.
Author Langarica, Saul
Kniss, Ariel S
Lamb, Leslie R
Do, Synho
Bahl, Manisha
Author_xml – sequence: 1
  givenname: Manisha
  orcidid: 0000-0002-7728-7690
  surname: Bahl
  fullname: Bahl, Manisha
  organization: Department of Radiology, Massachusetts General Hospital, 55 Fruit St, WAC 240, Boston, MA 02114
– sequence: 2
  givenname: Saul
  orcidid: 0000-0002-1763-0135
  surname: Langarica
  fullname: Langarica, Saul
  organization: Now with Department of Electrical Engineering, Pontificia Universidad Católica de Chile, Santiago, Chile
– sequence: 3
  givenname: Leslie R
  orcidid: 0000-0002-4024-7302
  surname: Lamb
  fullname: Lamb, Leslie R
  organization: Department of Radiology, Massachusetts General Hospital, 55 Fruit St, WAC 240, Boston, MA 02114
– sequence: 4
  givenname: Ariel S
  orcidid: 0009-0003-4493-3881
  surname: Kniss
  fullname: Kniss, Ariel S
  organization: Department of Radiology, Massachusetts General Hospital, 55 Fruit St, WAC 240, Boston, MA 02114
– sequence: 5
  givenname: Synho
  orcidid: 0000-0001-6211-7050
  surname: Do
  fullname: Do, Synho
  organization: Department of Radiology, Massachusetts General Hospital, 55 Fruit St, WAC 240, Boston, MA 02114
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40728399$$D View this record in MEDLINE/PubMed
BookMark eNo1j11LwzAYhYMo7kMvvZX8gc68-Wjayzm_CoPBnNcjTd7OSpuOJBP27y2oVwcOz3ngzMilHzwScgdsASCLh2BcO3QLLoEpdkGmoLjOQICakFmMX4yBVIW-JhPJNC9EWU7JZlnRNNAtupNFmj6RVj5h-DYdXRlvMdCtSUiHhr7bgOhbf6BP7aFNI_AY0MREd0M_xLMft7GNN-SqMV3E27-ck4-X593qLVtvXqvVcp1ZriBlNbjGYYkgFBgLrBRWCiVz6XjuoHaltqYQquBjjVhoY2upAHM0ouFOcz4n97_e46nu0e2Poe1NOO__n_EfOpBQXg
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1148/radiol.241050
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1527-1315
ExternalDocumentID 40728399
Genre Journal Article
GroupedDBID ---
.55
.GJ
123
18M
1CY
1KJ
29P
2WC
34G
39C
4.4
53G
5RE
6NX
6PF
7FM
AAEJM
AAQQT
AAWTL
ABDPE
ABHFT
ABOCM
ACFQH
ACGFO
ACJAN
ADBBV
AENEX
AENYM
AFFNX
AFOSN
AJJEV
AJWWR
ALMA_UNASSIGNED_HOLDINGS
BAWUL
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBS
ECM
EIF
EJD
F5P
F9R
GX1
H13
J5H
KO8
L7B
LMP
LSO
MJL
MV1
N4W
NPM
OK1
P2P
R.V
RKKAF
RXW
SJN
TAE
TR2
TRS
TWZ
W8F
WH7
WOQ
X7M
YQI
YQJ
ZGI
ZVN
ZXP
ID FETCH-LOGICAL-c251t-b1dfde9e1351ac1093c435464d26d1bd97ca83582c43ee87acb451e6ea3f2d722
IngestDate Mon Aug 04 01:30:50 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c251t-b1dfde9e1351ac1093c435464d26d1bd97ca83582c43ee87acb451e6ea3f2d722
ORCID 0000-0002-1763-0135
0009-0003-4493-3881
0000-0001-6211-7050
0000-0002-4024-7302
0000-0002-7728-7690
PMID 40728399
ParticipantIDs pubmed_primary_40728399
PublicationCentury 2000
PublicationDate 2025-07-01
PublicationDateYYYYMMDD 2025-07-01
PublicationDate_xml – month: 07
  year: 2025
  text: 2025-07-01
  day: 01
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Radiology
PublicationTitleAlternate Radiology
PublicationYear 2025
SSID ssj0014587
Score 2.4901354
Snippet Background Given the lack of long-term outcome data for screening digital breast tomosynthesis (DBT), the interval cancer rate is a commonly used surrogate for...
SourceID pubmed
SourceType Index Database
StartPage e241050
SubjectTerms Adult
Aged
Algorithms
Artificial Intelligence
Breast - diagnostic imaging
Breast Neoplasms - diagnostic imaging
Early Detection of Cancer - methods
Female
Humans
Mammography - methods
Middle Aged
Radiographic Image Interpretation, Computer-Assisted - methods
Retrospective Studies
Sensitivity and Specificity
Title AI to Reduce the Interval Cancer Rate of Screening Digital Breast Tomosynthesis
URI https://www.ncbi.nlm.nih.gov/pubmed/40728399
Volume 316
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JT-swELZYJMQFsT125AM3FGhSx06OZRM7Ul-RuKGJ7UAlmiBaIcGvZyZOGsqix-MSVXZdtf6-Tj5PZmFsq6FlBKFQXpKahic0HlgTJUMPb006tRZkU5ND_-JSHl-L05vwpnZlF9klg2RHv36ZV_IbVHEMcaUs2f9AdvihOICvEV-8IsJ4_RHGrROSjm2qvmrrMMhn8gcQmE_bbXBRAH81hdeQV-Cge0dtQhBTatqz3cl7ef8lw7X9bv-9UG2D6Y543Pfg_sEl92TUsHkYyAPZHZAtde7lOszwHHrFo55zi0rW1nGJZ7jcdUDGQ_pD6Xkt3Q5BOAxRxbtGaSoD5flNl4xZ2dKmS5wcIY2zjDaggNLG11ZbUCbCU_HDdj6_Dzf9sVdASNXcUNHF_579UES7mhpn40pRh49LcuqUD5tEGKmq_KqIdke-xzSbqtZ-OHgUAqQzy2bKkwNvORrMsTGbzbOpizI2YoFdtU74IOeODRwR5RUbuGMDJzbwPOVDNvCSDdyxgY-wYZFdHx129o-9sl2Gp1GkDrzEN6mxsaWei6CpTJhGLSykMIE0fmJipSGixGgctjZSoBMR-lZaaKaBUUHwh01keWaXGUczH0cSqAuXTwoPYpFKA0JBZGJIwhW25Lbi9tHVRLmtNmn125k1Nl3zaJ1NpvgntBuo6AbJZoHHG6gGSk0
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=AI+to+Reduce+the+Interval+Cancer+Rate+of+Screening+Digital+Breast+Tomosynthesis&rft.jtitle=Radiology&rft.au=Bahl%2C+Manisha&rft.au=Langarica%2C+Saul&rft.au=Lamb%2C+Leslie+R&rft.au=Kniss%2C+Ariel+S&rft.date=2025-07-01&rft.eissn=1527-1315&rft.volume=316&rft.issue=1&rft.spage=e241050&rft_id=info:doi/10.1148%2Fradiol.241050&rft_id=info%3Apmid%2F40728399&rft_id=info%3Apmid%2F40728399&rft.externalDocID=40728399